BIGG

The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance

World Health Organization.

The aim of this guidance is to provide the interim principles that should guide the use of delamanid in conjunction with WHO-recommended MDR-TB treatment. It also specifies the essential treatment and management conditions for use of this drug, in particular the patient's eligibility criteria and safety ...

Análisis Costo-Beneficio, Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico, Quimioterapia Combinada, Nitroimidazoles/uso terapéutico, Resultado del Tratamiento, Antituberculosos/uso terapéutico, Tuberculosis Pulmonar/tratamiento farmacológico, Ensayos Clínicos como Asunto, Nitroimidazoles/economía, Antituberculosos/economía

Texto completo

The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: Interim policy guidance

WHO estimates that up to half a million new cases of multidrug-resistant tuberculosis (MDR-TB) occur worldwide, each year. Current treatment regimens for MDR-TB present many challenges: treatment lasts 20 months or more, requiring daily administration of drugs that are more toxic, less effective, and far...